Association Between Enteral Supplementation With High-Dose Docosahexaenoic Acid and Risk of Bronchopulmonary Dysplasia in Preterm Infants
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.3934 ↗Kurz gefasst
Metaanalyse in der Zeitschrift JAMA Network Open, 2023. Verfasst von Isabelle Marc und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Québec, Canada. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Infant, Premature, Diseases. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.
Themen: Neonatologie
Abstract (Originalsprache)
Importance High-dose docosahexaenoic acid (DHA), a long-chain polyunsaturated fatty acid, may affect the risk of bronchopulmonary dysplasia (BPD). However, high-level summative evidence supporting such clinical association in very preterm infants is lacking.
Objective
To examine the association between enteral supplementation with high-dose DHA during the neonatal period and the risk of BPD in preterm infants born at less than 29 weeks’ gestation. Data Sources PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, medRxiv, and ClinicalTrials.gov were searched from inception to August 1, 2022, for eligible articles with no language restrictions. Study Selection Randomized clinical trials (RCTs) were eligible for inclusion (1) if their interventions involved direct administration of a minimum DHA supplementation of 40 mg/kg/d or breast milk or formula feeding of at least 0.4% of total fatty acids, and (2) if they reported data on either BPD, death, BPD severity, or a combined outcome of BPD and death. Data Extraction and Synthesis Two investigators completed independent review of titles and abstracts, full text screening, data extraction, and quality assessment using the Cochrane Risk of Bias 2.0. Risk ratios (RRs) with 95% CIs were pooled using random-effect meta-analyses. Main Outcomes and Measures Primary outcome was BPD using trial-specific definitions, which was further stratified for RCTs that used a more stringent BPD definition based on systematic pulse oximetry assessment at 36 weeks’ postmenstrual age. Other outcomes were BPD, death, BPD severity, or combined BPD and death.
Results
Among the 2760 studies screened, 4 RCTs were included, which involved 2304 infants (1223 boys [53.1%]; mean [SD] gestational age, 26.5 [1.6] weeks). Enteral supplementation with high-dose DHA was associated with neither BPD (4 studies [n = 2186 infants]; RR, 1.07 [95% CI, 0.86-1.34]; P = .53; I 2 = 72%) nor BPD or death (4 studies [n = 2299 infants]; RR, 1.04 [95% CI, 0.91-1.18]; P = .59; I 2 = 61%). However, an inverse association with BPD was found in RCTs that used a more stringent BPD definition (2 studies [n = 1686 infants]; RR, 1.20 [95% CI, 1.01-1.42]; P = .04; I 2 = 48%). Additionally, DHA was inversely associated with moderate-to-severe BPD (3 studies [n = 1892 infants]; RR, 1.16 [95% CI, 1.04-1.29]; P = .008; I 2 = 0%). Conclusions and Relevance Results of this study showed that enteral supplementation with high-dose DHA in the neonatal period was not associated overall with BPD, but an inverse association was found in the included RCTs that used a more stringent BPD definition. These findings suggest that high-dose DHA supplementation should not be recommended to prevent BPD in very preterm infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Québec, Canada.
- Library, Université Laval, Québec, Québec, Canada.
- Department of Social and Preventive Medicine, Université Laval, Québec, Québec, Canada.
- Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
- School of Public Health, University of Adelaide, Adelaide, South Australia, Australia.
- Department of Pediatrics, Division of Neonatology, University of British Columbia, Vancouver, British Columbia, Canada.
Förderung
- CIHR
Zitieren
APA
Marc, I., Boutin, A., Pronovost, E., Perez Herrera, N. M., Guillot, M., Bergeron, F., Moore, L., Sullivan, T. R., Lavoie, P. M., & Makrides, M. (2023). Association Between Enteral Supplementation With High-Dose Docosahexaenoic Acid and Risk of Bronchopulmonary Dysplasia in Preterm Infants. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.3934
Vancouver
Marc I, Boutin A, Pronovost E, Perez Herrera NM, Guillot M, Bergeron F, et al. Association Between Enteral Supplementation With High-Dose Docosahexaenoic Acid and Risk of Bronchopulmonary Dysplasia in Preterm Infants. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.3934
BibTeX
@article{Marc2023,
author = {Marc, Isabelle and Boutin, Amélie and Pronovost, Etienne and Perez Herrera, Norma Maria and Guillot, Mireille and Bergeron, Frédéric and Moore, Lynne and Sullivan, Thomas R and Lavoie, Pascal M and Makrides, Maria},
title = {Association Between Enteral Supplementation With High-Dose Docosahexaenoic Acid and Risk of Bronchopulmonary Dysplasia in Preterm Infants},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.3934}
}
EUVIMED